IL112834A - Pharmaceutical compositions for controlled release of soluble receptors - Google Patents

Pharmaceutical compositions for controlled release of soluble receptors

Info

Publication number
IL112834A
IL112834A IL11283495A IL11283495A IL112834A IL 112834 A IL112834 A IL 112834A IL 11283495 A IL11283495 A IL 11283495A IL 11283495 A IL11283495 A IL 11283495A IL 112834 A IL112834 A IL 112834A
Authority
IL
Israel
Prior art keywords
pct
controlled release
pharmaceutical compositions
soluble receptors
ligand
Prior art date
Application number
IL11283495A
Other languages
English (en)
Other versions
IL112834A0 (en
Inventor
David Wallach
Joseph Kost
Rom Eliaz
Original Assignee
Yeda Res & Dev
Univ Ben Gurion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Univ Ben Gurion filed Critical Yeda Res & Dev
Priority to IL11283495A priority Critical patent/IL112834A/xx
Publication of IL112834A0 publication Critical patent/IL112834A0/xx
Priority to UA97094438A priority patent/UA44761C2/uk
Priority to AU53039/96A priority patent/AU692384B2/en
Priority to DE69637768T priority patent/DE69637768D1/de
Priority to PT96909604T priority patent/PT812208E/pt
Priority to MX9706626A priority patent/MX9706626A/es
Priority to EP96909604A priority patent/EP0812208B1/de
Priority to KR1019970706046A priority patent/KR100417650B1/ko
Priority to CNB961934379A priority patent/CN1133464C/zh
Priority to PCT/US1996/003121 priority patent/WO1996026738A1/en
Priority to JP52645796A priority patent/JP4447052B2/ja
Priority to AT96909604T priority patent/ATE415941T1/de
Priority to US08/894,913 priority patent/US6083534A/en
Priority to BR9607289A priority patent/BR9607289A/pt
Priority to EA199700206A priority patent/EA199700206A1/ru
Priority to ES96909604T priority patent/ES2318849T3/es
Priority to DK96909604T priority patent/DK0812208T3/da
Priority to CA2213560A priority patent/CA2213560C/en
Priority to NO19973812A priority patent/NO323003B1/no
Publication of IL112834A publication Critical patent/IL112834A/xx
Priority to NO20056197A priority patent/NO328034B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL11283495A 1995-03-01 1995-03-01 Pharmaceutical compositions for controlled release of soluble receptors IL112834A (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
IL11283495A IL112834A (en) 1995-03-01 1995-03-01 Pharmaceutical compositions for controlled release of soluble receptors
UA97094438A UA44761C2 (uk) 1995-03-01 1996-01-03 ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ІЗ КОНТРОЛЬОВАНИМ ВИДІЛЕННЯМ РОЗЧИННОГО TNF-<font face="Symbol">a</font> РЕЦЕПТОРА ТА СПОСОБИ ЛІКУВАННЯ
CA2213560A CA2213560C (en) 1995-03-01 1996-03-01 Pharmaceutical compositions for controlled release of soluble receptors
CNB961934379A CN1133464C (zh) 1995-03-01 1996-03-01 控制释放可溶性受体的药物组合物
AT96909604T ATE415941T1 (de) 1995-03-01 1996-03-01 Arzneitmittel zur kontrollierten freisetzung löslicher rezeptoren
PT96909604T PT812208E (pt) 1995-03-01 1996-03-01 Composições farmacêuticas para libertação controlada de receptores solúveis
MX9706626A MX9706626A (es) 1995-03-01 1996-03-01 Composiciones farmaceuticas para la liberacion controlada de receptores solubles.
EP96909604A EP0812208B1 (de) 1995-03-01 1996-03-01 Arzneitmittel zur kontrollierten freisetzung löslicher rezeptoren
KR1019970706046A KR100417650B1 (ko) 1995-03-01 1996-03-01 가용성수용기의조절방출용약제조성물
AU53039/96A AU692384B2 (en) 1995-03-01 1996-03-01 Pharmaceutical compositions for controlled release of soluble receptors
PCT/US1996/003121 WO1996026738A1 (en) 1995-03-01 1996-03-01 Pharmaceutical compositions for controlled release of soluble receptors
JP52645796A JP4447052B2 (ja) 1995-03-01 1996-03-01 可溶性レセプターの制御された放出のための医薬組成物
DE69637768T DE69637768D1 (de) 1995-03-01 1996-03-01 Arzneitmittel zur kontrollierten freisetzung löslicher rezeptoren
US08/894,913 US6083534A (en) 1995-03-01 1996-03-01 Pharmaceutical compositions for controlled release of soluble receptors
BR9607289A BR9607289A (pt) 1995-03-01 1996-03-01 Composiçoes farmacêuticas para administraçao controlada de receptores solúveis
EA199700206A EA199700206A1 (ru) 1995-03-01 1996-03-01 Фармацевтические композиции для контролируемого высвобождения растворимых рецепторов
ES96909604T ES2318849T3 (es) 1995-03-01 1996-03-01 Composiciones farmaceuticas para el suministro controlado de receptores solubles.
DK96909604T DK0812208T3 (da) 1995-03-01 1996-03-01 Farmaceutiske sammensætninger til kontrolleret frigivelse af oplöselige receptorer
NO19973812A NO323003B1 (no) 1995-03-01 1997-08-19 Farmasoytiske sammensetninger til svekkelse av de skadelige effekter av Tumor Nekrose Faktor-alfa (TNF-alfa) samt anvendelse derav.
NO20056197A NO328034B1 (no) 1995-03-01 2005-12-27 Farmasoytiske sammensetninger for kontrollert frigjoring av TNF-alfa

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11283495A IL112834A (en) 1995-03-01 1995-03-01 Pharmaceutical compositions for controlled release of soluble receptors

Publications (2)

Publication Number Publication Date
IL112834A0 IL112834A0 (en) 1995-06-29
IL112834A true IL112834A (en) 2000-12-06

Family

ID=11067150

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11283495A IL112834A (en) 1995-03-01 1995-03-01 Pharmaceutical compositions for controlled release of soluble receptors

Country Status (19)

Country Link
US (1) US6083534A (de)
EP (1) EP0812208B1 (de)
JP (1) JP4447052B2 (de)
KR (1) KR100417650B1 (de)
CN (1) CN1133464C (de)
AT (1) ATE415941T1 (de)
AU (1) AU692384B2 (de)
BR (1) BR9607289A (de)
CA (1) CA2213560C (de)
DE (1) DE69637768D1 (de)
DK (1) DK0812208T3 (de)
EA (1) EA199700206A1 (de)
ES (1) ES2318849T3 (de)
IL (1) IL112834A (de)
MX (1) MX9706626A (de)
NO (2) NO323003B1 (de)
PT (1) PT812208E (de)
UA (1) UA44761C2 (de)
WO (1) WO1996026738A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
BR9509985A (pt) 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
EP1206275B1 (de) * 1998-11-05 2007-09-05 Omeros Corporation Spüllösung und verfahren zur schmerzlinderung und entzündungshemmung
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US7807211B2 (en) * 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
EP1216037A2 (de) * 1999-09-21 2002-06-26 Emory University Verfahren und zusammensetzungen zur behandlung von bluttplätchen-zusammenhängenden krankheiten, mit mpl hemmenden agenten
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US8632845B2 (en) * 2000-12-28 2014-01-21 Abbott Cardiovascular Systems Inc. Method of drying bioabsorbable coating over stents
PT1471974E (pt) * 2002-02-06 2007-10-12 Ares Trading Sa Factor de necrose tumural combinado com interferão em doenças desmielinizantes
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
CA2490007C (en) * 2002-07-19 2011-05-24 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
CA2520613C (en) 2003-03-31 2012-12-04 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
US7892563B2 (en) * 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US20060046960A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
US20060046961A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
CN1311818C (zh) * 2004-11-22 2007-04-25 山东蓝金生物工程有限公司 一种抗实体肿瘤的药物组合物
EP1827108B1 (de) * 2004-11-29 2015-04-08 Yeda Research And Development Co., Ltd. Induktion der neurogenese und stammzellentherapie in kombination mit copolymer 1
US8128952B2 (en) * 2005-01-12 2012-03-06 Clemson University Research Foundation Ligand-mediated controlled drug delivery
EP1896072A4 (de) * 2005-06-24 2013-01-09 Univ Duke System zur direkten heilmittelverabreichung auf der basis wärmegesteuerter biopolymere
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
US20090183503A1 (en) * 2008-01-18 2009-07-23 Alberto Verdesi Exhaust apparatus
BRPI0910850B1 (pt) 2008-04-21 2022-06-14 Otonomy, Inc. Composição intratimpânica compreendendo fator neurotrófico de crescimento derivado do cérebro (bdnf) para o tratamento ou prevenção da perda auditiva
GB2460915B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
CN102105133B (zh) 2008-07-21 2015-06-17 奥德纳米有限公司 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法
EP2688910B1 (de) 2011-03-25 2019-05-29 Amgen Inc. Anti-sclerostin-antikörperkristalle und formulierungen davon
EP2844668A1 (de) * 2012-05-03 2015-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung und diagnose von anämie im zusammenhang mit entzündungen
WO2014046631A1 (en) 2012-09-19 2014-03-27 Tezcaner Aysen CONTROLED DRUG DELIVERY SYSTEMS FOR ANTI-TNF-α
WO2015119653A1 (en) 2014-02-04 2015-08-13 Abbott Cardiovascular Systems Inc. Drug delivery scaffold or stent with a novolimus and lactide based coating such that novolimus has a minimum amount of bonding to the coating
EP3169710A1 (de) 2014-07-14 2017-05-24 Amgen Inc. Kristalline antikörperformulierungen
WO2016010924A1 (en) 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US9764122B2 (en) 2014-07-25 2017-09-19 Warsaw Orthopedic, Inc. Drug delivery device and methods having an occluding member
WO2017019907A1 (en) 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
JP5938762B1 (ja) 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
USD802755S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
KR20190024983A (ko) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 트리글리세라이드 귀 제제 및 이의 용도
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
CA3087574A1 (en) 2018-01-09 2019-07-18 Otonomy, Inc. Growth factor otic formulations
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
WO2019226519A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
AU2019275406B2 (en) 2018-05-24 2024-11-14 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2022231930A1 (en) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
SE8804164A0 (sv) * 1988-11-17 1990-05-18 Per Prisell Farmaceutisk beredning
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5478564A (en) * 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5470582A (en) * 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
EP0620739A4 (en) * 1992-09-15 1997-01-15 Immunex Corp Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists.
EP0646000A4 (de) * 1992-11-16 1997-05-02 Univ Mercer Zusammensetzungen, die mikroverkapselte neutralisierende antikörper enthalten.

Also Published As

Publication number Publication date
IL112834A0 (en) 1995-06-29
MX9706626A (es) 1998-02-28
CN1182369A (zh) 1998-05-20
DE69637768D1 (de) 2009-01-15
PT812208E (pt) 2009-02-06
NO323003B1 (no) 2006-12-18
JPH11501306A (ja) 1999-02-02
JP4447052B2 (ja) 2010-04-07
NO973812L (no) 1997-11-03
ES2318849T3 (es) 2009-05-01
EP0812208B1 (de) 2008-12-03
ATE415941T1 (de) 2008-12-15
NO328034B1 (no) 2009-11-16
NO973812D0 (no) 1997-08-19
AU5303996A (en) 1996-09-18
US6083534A (en) 2000-07-04
CA2213560A1 (en) 1996-09-06
EA199700206A1 (ru) 1998-02-26
CA2213560C (en) 2010-08-24
AU692384B2 (en) 1998-06-04
EP0812208A1 (de) 1997-12-17
BR9607289A (pt) 1998-06-23
KR19980702640A (ko) 1998-08-05
EP0812208A4 (de) 2004-06-30
CN1133464C (zh) 2004-01-07
KR100417650B1 (ko) 2004-05-20
NO20056197L (no) 1997-11-03
DK0812208T3 (da) 2009-03-16
UA44761C2 (uk) 2002-03-15
WO1996026738A1 (en) 1996-09-06

Similar Documents

Publication Publication Date Title
IL112834A0 (en) Pharmaceutical compositions for controlled release of soluble receptors
US4968317B1 (en) Surgical materials and devices
GB2246295B (en) Continuous release pharmaceutical compositions
IS2034B (is) Ný lyfjablanda til inntöku um munn sem inniheldurnýtt magnesíumsalt ómeprasóls, aðferð við framleiðslu hennar og notkun
NZ291417A (en) Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri
TW228474B (de)
IL134268A0 (en) Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use
GR3030032T3 (en) Human il-3 variants.
IL115138A (en) Implantable polymer-containing molded articles for the administration of active substances to plants and processes for the preparation thereof
DE69634080D1 (de) Mittel zur verhinderung der truebung der vorderen linsenkapsel
GR3006966T3 (en) Pharmaceutical composition comprising a medicament and a water-swellable polymer
GEP20032906B (en) Controlled Release Peroral Pharmaceutical Composition of Levosimendan for Treatment of Congestive Heart Failure
AU5766790A (en) Liquid polymer composition, and method of use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired